BioArctic AB (publ) (STO:BIOA.B)
271.00
-13.20 (-4.64%)
Nov 5, 2025, 4:29 PM CET
BioArctic AB Employees
BioArctic AB had 107 employees as of December 31, 2024. The number of employees increased by 19 or 21.59% compared to the previous year.
Employees
107
Change (1Y)
19
Growth (1Y)
21.59%
Revenue / Employee
15.63M SEK
Profits / Employee
8.97M SEK
Market Cap
25.19B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107 | 19 | 21.59% |
| Dec 31, 2023 | 88 | 27 | 44.26% |
| Dec 31, 2022 | 61 | 12 | 24.49% |
| Dec 31, 2021 | 49 | 4 | 8.89% |
| Dec 31, 2020 | 45 | 3 | 7.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Medicover AB | 47,256 |
| Getinge AB | 11,791 |
| Nolato AB | 5,837 |
| Elekta AB | 4,556 |
| Asker Healthcare Group AB | 4,030 |
| AddLife AB | 2,181 |
| Swedish Orphan Biovitrum AB | 1,806 |
| Sectra AB | 1,296 |
BioArctic AB News
- 1 day ago - Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET - PRNewsWire
- 6 days ago - Sales of Leqembi® totaled 18 billion yen in the third quarter 2025 - PRNewsWire
- 9 days ago - Health Canada Grants Authorization for Leqembi® (lecanemab) - PRNewsWire
- 22 days ago - Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 - PRNewsWire
- 4 weeks ago - Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. - PRNewsWire
- 5 weeks ago - Leqembi® approved for IV maintenance treatment in China - PRNewsWire
- 6 weeks ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - Benzinga
- 6 weeks ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - PRNewsWire